Though no consensus was reached regarding the suitability of prescribing only certain types of SGLT2 inhibitors to patients with a history of diabetes‐related ulcers, participants agreed that canagliflozin should not be prescribed to patients with current or previous foot ulceration or amputation. This evidence concerns the gene SLC5A2 and diabetes mellitus.